LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Selective Use of D-Dimer Test for Deep Vein Thrombosis

By LabMedica International staff writers
Posted on 30 Jan 2013
D-dimer testing based on clinical pretest probability for deep vein thrombosis (DVT) is safe and reduces diagnostic testing compared with checking all patients.

D-dimer testing is sensitive but not specific for DVT and changing the threshold level for a positive test result based on risk for DVT might improve the tradeoff between sensitivity and specificity and reduce the need for testing.

Scientists from McMaster University, (Hamilton, ON, Canada) randomly assigned 1,723 outpatients presenting for the first time with symptoms of DVT to selective testing for D-dimer for patients with low or moderate clinical pretest probability of DVT. Some patients with high clinical pretest probability had venous ultrasonograpy without D-dimer testing and some patients presenting with symptoms had uniform testing. The study groups were all consecutive symptomatic patients with a first episode of suspected DVT from five different hospitals.

Selective testing of 860 patients, defined as d-dimer testing for outpatients with low or moderate clinical pretest probability (C-PTP), where DVT excluded at d-dimer levels of equal to or less than 1.0 µg/mL, a low C-PTP or equal to or less than 0.5 µg/mL, moderate C-PTP. The groups who had venous ultrasonography without d-dimer testing for outpatients with high C-PTP and inpatients, or the 863 uniform testing defined as d-dimer testing for all participants where DVT was excluded at d-dimer levels of less than 0.51 µg/mL.

The incidence of symptomatic venous thromboembolism at three months was 0.5% in both study groups. Selective testing reduced the proportion of patients who required d-dimer testing by 21.8% and reduced the proportion that required ultrasonography by 7.6 % overall and by 21.0% in outpatients with low C-PTP. The authors concluded that a selective d-dimer testing strategy seems as safe as and more efficient than having everyone undergo d-dimer testing when diagnosing a first episode of suspected DVT. The study was published on January 15, 2013, in the journal Annals of Internal Medicine.

Related Links:

McMaster University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more